GSK's Exdensur Approved in China for Chronic Rhinosinusitis with Nasal Polyps

summarizeSummary

China's NMPA has approved GSK's Exdensur (depemokimab) for chronic rhinosinusitis with nasal polyps (CRSwNP), making it the first and only ultra-long-acting biologic for this condition in China.

check_boxKey Events

• NMPA Approval for Exdensur

  China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) for chronic rhinosinusitis with nasal polyps (CRSwNP) as an add-on therapy with intranasal corticosteroids.

• First Ultra-Long-Acting Biologic

  Exdensur is the first and only ultra-long-acting biologic approved in China for CRSwNP, offering a convenient twice-yearly dosing schedule.

• Based on Positive Phase III Trials

  The approval is supported by data from the ANCHOR-1 and ANCHOR-2 phase III trials, which demonstrated clinically meaningful and statistically significant improvements in nasal polyp size and nasal obstruction.

• Market Expansion in China

  This approval follows Exdensur's recent NMPA approval for severe asthma, further expanding its market presence and commercial potential in China for a new indication.

auto_awesomeAnalysis

This approval significantly expands the market for Exdensur in China, building on its recent approval for severe asthma. As the first and only ultra-long-acting biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) in China, Exdensur addresses a substantial unmet medical need. This development, backed by robust Phase III trial data, strengthens GSK's respiratory portfolio and is expected to positively impact the company's commercial prospects in the region.